paclitaxel
Phase 2- Indications
- Actinic keratosis, Cutaneous metastases
Company intelligence / Profile preview
DFB Soria
Fort Worth, Texas, United Statesamarillo-chamber.org ↗
- Ownership
- Private
- Development stage
- Phase 2
01
Overview
The company completed a Phase II dose-escalation trial evaluating topical submicron particle paclitaxel ointment ("SOR007") for actinic keratosis. Results showed reduction in lesion size/count with minimal irritation or side effects. The product leverages a patented nanoparticle technology that increases surface area and allows better dermal penetration. The IP position is strong due to composition-of-matter patent protection through at least 2036. Further development options are being explored including potential partnerships or continued internal investment.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Small moleculesTopical ointmentsNanoparticles
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Exclusive worldwide license from CritiTech, Inc. for nanoparticle production technology outside oncology fields.Affiliated with NanOlogy™, which develops similar technologies primarily focused on oncology indications.
Beyond the preview
Go deeper on DFB Soria.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DFB Soria.